Annual FCF
-$4.27 M
-$124.20 M-103.56%
31 December 2023
Summary:
Ligand Pharmaceuticals Incorporated annual free cash flow is currently -$4.27 million, with the most recent change of -$124.20 million (-103.56%) on 31 December 2023. During the last 3 years, it has fallen by -$54.40 million (-108.52%). LGND annual FCF is now -102.33% below its all-time high of $183.17 million, reached on 31 December 2018.LGND Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
$22.29 M
+$11.11 M+99.45%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated quarterly free cash flow is currently $22.29 million, with the most recent change of +$11.11 million (+99.45%) on 30 September 2024. Over the past year, it has increased by +$15.13 million (+211.34%). LGND quarterly FCF is now -69.73% below its all-time high of $73.64 million, reached on 30 June 2018.LGND Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
$6.97 M
+$15.13 M+185.37%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated TTM free cash flow is currently $6.97 million, with the most recent change of +$15.13 million (+185.37%) on 30 September 2024. Over the past year, it has dropped by -$83.74 million (-92.32%). LGND TTM FCF is now -96.41% below its all-time high of $194.06 million, reached on 31 December 2018.LGND TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LGND Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -103.6% | +211.3% | -92.3% |
| 3 y3 years | -108.5% | +22.1% | -84.0% |
| 5 y5 years | -102.3% | +459.7% | -34.1% |
LGND Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -103.6% | at low | -57.4% | +152.2% | -94.2% | +135.5% |
| 5 y | 5 years | -102.3% | +86.6% | -57.4% | +152.2% | -94.2% | +112.1% |
| alltime | all time | -102.3% | +97.0% | -69.7% | +118.9% | -96.4% | +103.7% |
Ligand Pharmaceuticals Incorporated Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $22.29 M(+99.5%) | $6.97 M(-185.4%) |
| June 2024 | - | $11.18 M(-31.0%) | -$8.16 M(-58.4%) |
| Mar 2024 | - | $16.18 M(-137.9%) | -$19.62 M(+359.3%) |
| Dec 2023 | -$4.27 M(-103.6%) | -$42.68 M(-696.2%) | -$4.27 M(-104.7%) |
| Sept 2023 | - | $7.16 M(-2611.9%) | $90.71 M(-8.1%) |
| June 2023 | - | -$285.00 K(-100.9%) | $98.75 M(-5.3%) |
| Mar 2023 | - | $31.53 M(-39.7%) | $104.33 M(-13.0%) |
| Dec 2022 | $119.93 M(+71.2%) | $52.30 M(+244.1%) | $119.93 M(+28.9%) |
| Sept 2022 | - | $15.20 M(+187.3%) | $93.07 M(-3.2%) |
| June 2022 | - | $5.29 M(-88.8%) | $96.13 M(-12.5%) |
| Mar 2022 | - | $47.14 M(+85.2%) | $109.82 M(+56.8%) |
| Dec 2021 | $70.04 M(+39.7%) | $25.45 M(+39.4%) | $70.04 M(+61.0%) |
| Sept 2021 | - | $18.25 M(-3.9%) | $43.50 M(+21.0%) |
| June 2021 | - | $18.99 M(+158.3%) | $35.95 M(-11.4%) |
| Mar 2021 | - | $7.35 M(-772.5%) | $40.56 M(-19.1%) |
| Dec 2020 | $50.13 M(-257.2%) | -$1.09 M(-110.2%) | $50.13 M(+14.2%) |
| Sept 2020 | - | $10.71 M(-54.6%) | $43.88 M(+62.7%) |
| June 2020 | - | $23.59 M(+39.4%) | $26.98 M(-146.8%) |
| Mar 2020 | - | $16.92 M(-330.6%) | -$57.67 M(+96.6%) |
| Dec 2019 | -$31.89 M(-117.4%) | -$7.34 M(+18.4%) | -$29.34 M(-377.4%) |
| Sept 2019 | - | -$6.20 M(-89.9%) | $10.57 M(-75.9%) |
| June 2019 | - | -$61.06 M(-234.9%) | $43.85 M(-75.4%) |
| Mar 2019 | - | $45.26 M(+38.9%) | $178.56 M(-8.0%) |
| Dec 2018 | $183.17 M(+112.0%) | $32.57 M(+20.3%) | $194.06 M(+0.7%) |
| Sept 2018 | - | $27.08 M(-63.2%) | $192.80 M(-0.3%) |
| June 2018 | - | $73.64 M(+21.2%) | $193.37 M(+48.6%) |
| Mar 2018 | - | $60.76 M(+94.1%) | $130.11 M(+46.9%) |
| Dec 2017 | $86.41 M(+109.8%) | $31.31 M(+13.2%) | $88.57 M(+6.7%) |
| Sept 2017 | - | $27.65 M(+166.2%) | $82.97 M(+15.8%) |
| June 2017 | - | $10.39 M(-46.0%) | $71.66 M(+35.3%) |
| Mar 2017 | - | $19.22 M(-25.2%) | $52.98 M(+28.6%) |
| Dec 2016 | $41.19 M(+33.4%) | $25.71 M(+57.4%) | $41.19 M(+51.0%) |
| Sept 2016 | - | $16.34 M(-297.0%) | $27.27 M(+35.7%) |
| June 2016 | - | -$8.29 M(-211.6%) | $20.10 M(-40.8%) |
| Mar 2016 | - | $7.43 M(-37.0%) | $33.97 M(+10.1%) |
| Dec 2015 | $30.86 M(+92.1%) | $11.80 M(+28.8%) | $30.86 M(+15.4%) |
| Sept 2015 | - | $9.16 M(+64.1%) | $26.75 M(+27.0%) |
| June 2015 | - | $5.58 M(+29.2%) | $21.05 M(+8.3%) |
| Mar 2015 | - | $4.32 M(-43.7%) | $19.44 M(+21.0%) |
| Dec 2014 | $16.07 M(+2.0%) | $7.68 M(+121.6%) | $16.07 M(-17.2%) |
| Sept 2014 | - | $3.47 M(-12.5%) | $19.41 M(+26.2%) |
| June 2014 | - | $3.96 M(+315.9%) | $15.38 M(+4.9%) |
| Mar 2014 | - | $953.00 K(-91.4%) | $14.66 M(-6.9%) |
| Dec 2013 | $15.75 M(-285.7%) | $11.03 M(-2055.9%) | $15.75 M(+127.3%) |
| Sept 2013 | - | -$564.00 K(-117.4%) | $6.93 M(+155.4%) |
| June 2013 | - | $3.25 M(+59.0%) | $2.71 M(-280.3%) |
| Mar 2013 | - | $2.04 M(-7.6%) | -$1.50 M(-82.3%) |
| Dec 2012 | -$8.48 M(+105.6%) | $2.21 M(-146.2%) | -$8.48 M(+30.2%) |
| Sept 2012 | - | -$4.78 M(+391.0%) | -$6.51 M(+124.8%) |
| June 2012 | - | -$974.00 K(-80.3%) | -$2.90 M(-70.9%) |
| Mar 2012 | - | -$4.94 M(-218.1%) | -$9.97 M(+141.6%) |
| Dec 2011 | -$4.13 M(-85.5%) | $4.18 M(-458.5%) | -$4.13 M(-56.5%) |
| Sept 2011 | - | -$1.17 M(-85.5%) | -$9.48 M(-40.7%) |
| June 2011 | - | -$8.04 M(-988.0%) | -$15.99 M(+38.5%) |
| Mar 2011 | - | $906.00 K(-177.3%) | -$11.55 M(-59.3%) |
| Dec 2010 | -$28.38 M(-17.3%) | -$1.17 M(-84.7%) | -$28.38 M(-0.4%) |
| Sept 2010 | - | -$7.68 M(+113.2%) | -$28.49 M(-12.0%) |
| June 2010 | - | -$3.60 M(-77.4%) | -$32.37 M(+24.9%) |
| Mar 2010 | - | -$15.93 M(+1150.5%) | -$25.92 M(-24.5%) |
| Dec 2009 | -$34.32 M | -$1.27 M(-89.0%) | -$34.32 M(+27.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2009 | - | -$11.56 M(-506.4%) | -$26.90 M(-6.8%) |
| June 2009 | - | $2.84 M(-111.7%) | -$28.86 M(-19.5%) |
| Mar 2009 | - | -$24.34 M(-495.6%) | -$35.86 M(+69.8%) |
| Dec 2008 | -$21.12 M(-78.5%) | $6.15 M(-145.5%) | -$21.12 M(-41.5%) |
| Sept 2008 | - | -$13.52 M(+224.9%) | -$36.13 M(-2.0%) |
| June 2008 | - | -$4.16 M(-56.6%) | -$36.88 M(-40.8%) |
| Mar 2008 | - | -$9.60 M(+8.3%) | -$62.33 M(-36.5%) |
| Dec 2007 | -$98.17 M(-30.0%) | -$8.86 M(-37.9%) | -$98.17 M(-43.4%) |
| Sept 2007 | - | -$14.27 M(-51.8%) | -$173.57 M(-7.8%) |
| June 2007 | - | -$29.61 M(-34.8%) | -$188.24 M(+13.7%) |
| Mar 2007 | - | -$45.44 M(-46.1%) | -$165.56 M(+18.0%) |
| Dec 2006 | -$140.30 M(+415.2%) | -$84.26 M(+191.2%) | -$140.30 M(+217.1%) |
| Sept 2006 | - | -$28.94 M(+317.5%) | -$44.24 M(+3.6%) |
| June 2006 | - | -$6.93 M(-65.6%) | -$42.69 M(-3.4%) |
| Mar 2006 | - | -$20.17 M(-270.9%) | -$44.21 M(+62.4%) |
| Dec 2005 | -$27.23 M(-1366.6%) | $11.80 M(-143.1%) | -$27.23 M(+156.3%) |
| Sept 2005 | - | -$27.39 M(+224.0%) | -$10.62 M(-219.3%) |
| June 2005 | - | -$8.45 M(+164.7%) | $8.90 M(+91.8%) |
| Mar 2005 | - | -$3.19 M(-111.2%) | $4.64 M(+115.9%) |
| Dec 2004 | $2.15 M(-132.6%) | $28.41 M(-461.4%) | $2.15 M(-109.5%) |
| Sept 2004 | - | -$7.86 M(-38.2%) | -$22.72 M(+24.4%) |
| June 2004 | - | -$12.71 M(+123.7%) | -$18.27 M(+693.2%) |
| Mar 2004 | - | -$5.68 M(-260.6%) | -$2.30 M(-65.1%) |
| Dec 2003 | -$6.60 M(-95.2%) | $3.54 M(-203.9%) | -$6.60 M(-94.8%) |
| Sept 2003 | - | -$3.41 M(-204.9%) | -$128.07 M(-0.6%) |
| June 2003 | - | $3.25 M(-132.5%) | -$128.90 M(-10.9%) |
| Mar 2003 | - | -$9.98 M(-91.5%) | -$144.70 M(+6.1%) |
| Dec 2002 | -$136.35 M(+523.2%) | -$117.92 M(+2684.5%) | -$136.35 M(+510.3%) |
| Sept 2002 | - | -$4.24 M(-66.3%) | -$22.34 M(-11.5%) |
| June 2002 | - | -$12.56 M(+667.7%) | -$25.26 M(+165.5%) |
| Mar 2002 | - | -$1.64 M(-58.2%) | -$9.51 M(-56.5%) |
| Dec 2001 | -$21.88 M(-52.7%) | -$3.91 M(-45.2%) | -$21.88 M(-17.3%) |
| Sept 2001 | - | -$7.15 M(-324.3%) | -$26.46 M(-21.3%) |
| June 2001 | - | $3.19 M(-122.7%) | -$33.64 M(-27.0%) |
| Mar 2001 | - | -$14.01 M(+64.8%) | -$46.12 M(-0.4%) |
| Dec 2000 | -$46.30 M(-25.4%) | -$8.50 M(-40.7%) | -$46.30 M(-2.5%) |
| Sept 2000 | - | -$14.33 M(+54.3%) | -$47.50 M(-1.2%) |
| June 2000 | - | -$9.29 M(-34.6%) | -$48.08 M(-10.6%) |
| Mar 2000 | - | -$14.19 M(+46.3%) | -$53.79 M(-13.4%) |
| Dec 1999 | -$62.10 M(-10.0%) | -$9.70 M(-34.9%) | -$62.10 M(-11.5%) |
| Sept 1999 | - | -$14.90 M(-0.7%) | -$70.20 M(-2.4%) |
| June 1999 | - | -$15.00 M(-33.3%) | -$71.90 M(+1.8%) |
| Mar 1999 | - | -$22.50 M(+26.4%) | -$70.60 M(+2.3%) |
| Dec 1998 | -$69.00 M(+289.8%) | -$17.80 M(+7.2%) | -$69.00 M(+77.8%) |
| Sept 1998 | - | -$16.60 M(+21.2%) | -$38.80 M(+19.0%) |
| June 1998 | - | -$13.70 M(-34.4%) | -$32.60 M(+7.6%) |
| Mar 1998 | - | -$20.90 M(-268.5%) | -$30.30 M(+71.2%) |
| Dec 1997 | -$17.70 M(-47.5%) | $12.40 M(-219.2%) | -$17.70 M(-51.2%) |
| Sept 1997 | - | -$10.40 M(-8.8%) | -$36.30 M(+0.6%) |
| June 1997 | - | -$11.40 M(+37.3%) | -$36.10 M(+8.1%) |
| Mar 1997 | - | -$8.30 M(+33.9%) | -$33.40 M(-0.9%) |
| Dec 1996 | -$33.70 M(-11.5%) | -$6.20 M(-39.2%) | -$33.70 M(+22.5%) |
| Sept 1996 | - | -$10.20 M(+17.2%) | -$27.50 M(+59.0%) |
| June 1996 | - | -$8.70 M(+1.2%) | -$17.30 M(+101.2%) |
| Mar 1996 | - | -$8.60 M(+168.8%) | -$8.60 M(-43.0%) |
| Dec 1995 | -$38.10 M(+155.7%) | - | - |
| Mar 1995 | - | -$3.20 M(-28.9%) | -$15.10 M(+1.3%) |
| Dec 1994 | -$14.90 M | -$4.50 M(+45.2%) | -$14.90 M(+43.3%) |
| Sept 1994 | - | -$3.10 M(-27.9%) | -$10.40 M(+42.5%) |
| June 1994 | - | -$4.30 M(+43.3%) | -$7.30 M(+143.3%) |
| Mar 1994 | - | -$3.00 M | -$3.00 M |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual free cash flow?
- What is the all time high annual FCF for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual FCF year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly free cash flow?
- What is the all time high quarterly FCF for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly FCF year-on-year change?
- What is Ligand Pharmaceuticals Incorporated TTM free cash flow?
- What is the all time high TTM FCF for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated TTM FCF year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual free cash flow?
The current annual FCF of LGND is -$4.27 M
What is the all time high annual FCF for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual free cash flow is $183.17 M
What is Ligand Pharmaceuticals Incorporated annual FCF year-on-year change?
Over the past year, LGND annual free cash flow has changed by -$124.20 M (-103.56%)
What is Ligand Pharmaceuticals Incorporated quarterly free cash flow?
The current quarterly FCF of LGND is $22.29 M
What is the all time high quarterly FCF for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly free cash flow is $73.64 M
What is Ligand Pharmaceuticals Incorporated quarterly FCF year-on-year change?
Over the past year, LGND quarterly free cash flow has changed by +$15.13 M (+211.34%)
What is Ligand Pharmaceuticals Incorporated TTM free cash flow?
The current TTM FCF of LGND is $6.97 M
What is the all time high TTM FCF for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high TTM free cash flow is $194.06 M
What is Ligand Pharmaceuticals Incorporated TTM FCF year-on-year change?
Over the past year, LGND TTM free cash flow has changed by -$83.74 M (-92.32%)